Clear AllClose
Your cart is currently empty.
Sold out
-% Sale
You Save: (%)
This product was viewed 6 times within last hour

Dermal Repair Cream with CBD and CBG - 50ml

Short description

CBG and CBD cream benefits

The Dermal Repair Cream softens, heals and protects the skin. It is suitable for all skin types, especially for sensitive skin and is suitable for use on the face as well as the body. Includes CBD and CBG which co-work to optimise faster recovery times for the skin. In addition, CBD shows anti-inflammatory properties (see Research tab).

  • 50ml size
  • CBD, CBG, Cetomacrogol
  • 100% natural ingredients
  • Vegan, Gluten-free and GMO-free
  • UK GMP Compliant
Real time 22 visitor right now!
Hurry Up! Left in stock
Order in the next to get it by Fri, Oct 29, 2021

Availability: In stock

Tax Info: Tax included. Shipping calculated at checkout.

Dermal Repair Cream is infused with relatively high concentrations of cannabinoids like Cannabidiol (CBD) and Cannabigerol (CBG) which helps maintain healthy and radiant skin. Includes Multi-purpose Cannabinoid Molecules which support and balance the anti-inflammation process in the skin.

  • Softens, heals and protects the skin
  • Anti-inflammatory
  • Suitable for all skin including sensitive skin
  • Made from 100% natural EU hemp
  • Laboratory-tested for purity and cannabidiol and cannabigerol content
  • Manufactured and bottled in Consett, UK
Size 50ml
Cetomacrogol, Cannabidiol (CBD), Cannabigerol (CBG)
Active ingredients
Usage instruction Topical application on face or body
Manufactured Consett, UK
  • Apply cream as many times as needed on the skin.
  • Mostly 1-2 application’s a day are enough.
  • Store in a dry, cool, secured place out of reach of young children.
  • After opening use within 6 months.

The Dermal Repair Cream (Cetomacrogol based Cannabinoid infused cream) can be applied in a thin layer and should then be reapplied one, two or three times a day for as long as necessary. Once applied, the symptoms will be eased, after which the cream can simply be reapplied. Suddenly stopping use of the cream will not harm you.

Dermal Repair Cream has a wide possibility of use
  • Dry skin- Dry skin can occur, aggravated by sun exposure, or exposure to dry air, for example, with the use of central heating in winter. Sensitive areas are the face, hands, upper arms, thighs, hips and shins. This cream is an ideal choice as it both moisturisers and protects.
  • Eczema - With eczema, the skin is often dry, and this cream can be used. The use will reduce complaints such as burning spots, itching, splitting and flaking. It can also be prevented from scratching on the spots, so that the skin is less damaged.
  • Itching - Itching often occurs with dry skin, which can be prevented by one of the creams depending on the severity of the dryness. The cream will keep the skin more supple, once applied its beneficial effects can be quickly noticed.
  • Psoriasis - If the top layer of the skin grows too fast, it is called psoriasis. Flaking, thickening and inflammation of the skin then arises, often resulting in painful, inflamed and itchy skin. By using Cetomacrogol cream, the symptoms will decrease and sometimes even disappear completely.
  • Wounds - It’s important that wounds are kept sterile, and it is essential for healing. Cetomacrogol is the perfect compound for this healing process.
Consult a medical professional before use. Keep out of reach of children. Store in a cool dry place.

If you are pregnant or breastfeeding, we recommend that you do not use any CBD or CBG products.

If you have a medical condition or if you are on medication, always consult with your doctor before you start using CBD or CBG. If you have any allergies, please read the ingredients list carefully.

Both CBD and CBG have been found to display therapeutic effects in Inflammatory Bowel Disease:

Crohn’s Disease (Inflammatory Bowel Disease) can not be treated yet, but some pre-clinical studies conducted on mice in 2013 suggest that CBG seems to reduce the inflammation(4). Additionally, CBD is able to modulate the immune response to gut inflammation as described in a 2011 study(8). CBD and CBG are therefore regarded as a promising therapeutic agents in the treatment of inflammatory bowel disorders.

The CBG studies require more research, but some benefits have already been found in treatment of the following conditions:

  • Glaucoma - According to a study published in 2008(1) CBG reduces intraocular pressure and therefore it might be effective in treating Glaucoma
  • Bladder Dysfunction Aid - CBG was the most effective in the inhibition of muscle contractions inside the human bladder(2) according to study from 2015
  • Bacterial infections - Another study from 2008 shows that CBG may combat Staphylococcus aureus (MRSA)(3), a particularly resistant superbug bacteria
  • Loss of appetite - CBG can work as an appetite stimulant(5)

Here’s what the research says about using CBD

  • Epilepsy - Human trials completed in relation to epilepsy(6) have shown no seizures in patients who were taking the CBD
  • Nausea - CBD may be effective at reducing symptoms of nausea (based on rats and shrews studies from 2020)(7)
  • Anxiety and insomnia - CBD is also commonly used to address anxiety, and insomnia. Some studies suggest that CBD may help with both falling asleep and staying asleep(9)
  • Chronic pain - A study from 2018(10) examined the use of CBD among other medicines and found they might be of some benefit in the treatment of chronic neuropathic pain and inflammation due to arthritis.

(1) Krystyna Nadolska, Roman Goś, "Possibilities of applying cannabinoids' in the treatment of glaucoma", Published 2008, Medicine, Klinika oczna
(2) Ester Pagano, Vittorino Montanaro, Antonio Di Girolamo, Antonio Pistone, Vincenzo Altieri, Jordan K Zjawiony, Angelo A Izzo, Raffaele Capasso, "Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol", Published June 1, 2015, Natural Product Communications
(3) Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, and M. Mukhlesur Rahman, Antibacterial cannabinoids from Cannabis sativa: a structure-activity study, Published August 6, 2008, The American Chemical Society and American Society of Pharmacognosy
(4) Francesca Borrelli, Ines Fasolino, Barbara Romano, Raffaele Capasso, Francesco Maiello, Diana Coppola, Pierangelo Orlando, Giovanni Battista, Ester Pagano, Vincenzo Di Marzo, Angelo A Izzo "Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease", Published May 1, 2013, Biochemical pharmacology
(5) Daniel I Brierley, James Samuels, Marnie Duncan, Benjamin J Whalley, Claire M Williams, "Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats", Published in October 2016, Psychopharmacology
(6) J M Cunha, E A Carlini, A E Pereira, O L Ramos, C Pimentel, R Gagliardi, W L Sanvito, N Lander, R Mechoulam "Chronic Administration of cannabidiol to healthy volunteers and epileptic patients", Published in February 1980, Pharmacology
(7) Erin M Rock, Megan T Sullivan, Stephen A Collins, Hannah Goodman, Cheryl L Limebeer, Raphael Mechoulam, Linda A Parker, "Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews", Published June 2, 2020, Psychopharmacology
(8) Daniele De Filippis, Giuseppe Esposito, Carla Cirillo, Mariateresa Cipriano, Benedicte Y De Winter, Caterina Scuderi, Giovanni Sarnelli, Rosario Cuomo, Luca Steardo, Joris G De Man, Teresa Iuvone, "Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis", Published December 2011, PLoS ONE
(9) Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, "Cannabidiol in Anxiety and Sleep: A Large Case Series", Published January 7, 2019, The Permanente Journal
(10) Martin Mücke, Tudor Phillips, Lukas Radbruch, Frank Petzke, Winfried Häuser, "Cannabis‐based medicines for chronic neuropathic pain in adults", Published March 7, 2018, Cochrane database of systematic reviews